Novo’s Wegovy Demand Raises Grocer Fears Over Denmark Food Sales

In Novo Nordisk A/S’s home country of Denmark, the popularity of weight-loss drugs is fueling economic growth, but local retailers are now warning they will take a hit as food consumption declines.

Danish supermarkets could lose as much as 1.2 billion kroner ($187 million) in annual revenue as GLP-1-based drugs, like Novo’s Wegovy, become more widely used, according to a fresh analysis by DSK, a trade association for Danish grocers. The loss could turn out to be even deeper if the medicine becomes cheaper or more accessible, such as through a tablet form, the group said.